Influence of obesity in interstitial lung disease associated with anti-aminoacyl-tRNA synthetase antibodies

Yamaguchi, Kazutaka; Fukushima, Yasuhiro; Yamaguchi, Aiko; Itai, Miki; Shin, Yuki; Uno, Shogo; Muto, Sohei; Kouno, Shunichi; Tsurumaki, Hiroaki; Yatomi, Masakiyo; Aoki‐Saito, Haruka; Hara, Kenichiro; Koga, Yasuhiko; Sunaga, Noriaki; Endo, Yukie; Motegi, Sei‐ichiro; Nakasatomi, Masao; Sakairi, Toru; Ikeuchi, Hidekazu; Hiromura, Keiju; Hisada, Takeshi; Tsushima, Yoshito; Kuwana, Masataka; Maeno, Toshitaka

doi:10.1016/j.rmed.2022.106741

Cited by 4 publications

(1 citation statement)

References 43 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In anti-synthetase syndrome-associated ILD, an increased burden of thoracic subcutaneous adipose tissue is associated with higher risk of relapse, as well as increased burden of fibrosis on imaging [ 49 ]. Furthermore, in this same study, patients with higher levels of thoracic adiposity were found to have higher levels of circulating KL-6, a marker of pulmonary epithelial injury [ 49 , 50 ].…”

Section: Adiposity and Ild In Human Studiesmentioning

confidence: 99%

Linking Adiposity to Interstitial Lung Disease: The Role of the Dysfunctional Adipocyte and Inflammation

Macklin,

Thompson,

Kawano-Dourado

et al. 2023

Cells

View full text Add to dashboard Cite

Adipose tissue has functions beyond its principal functions in energy storage, including endocrine and immune functions. When faced with a surplus of energy, the functions of adipose tissue expand by mechanisms that can be both adaptive and detrimental. These detrimental adipose tissue functions can alter normal hormonal signaling and promote local and systemic inflammation with wide-ranging consequences. Although the mechanisms by which adipose tissue triggers metabolic dysfunction and local inflammation have been well described, little is known about the relationship between adiposity and the pathogenesis of chronic lung conditions, such as interstitial lung disease (ILD). In this review, we detail the conditions and mechanisms by which adipose tissue becomes dysfunctional and relate this dysfunction to inflammatory changes observed in various forms of ILD. Finally, we review the existing basic and clinical science literature linking adiposity to ILD, highlighting the need for additional research on the mechanisms of adipocyte-mediated inflammation in ILD and its clinical implications.

show abstract

Section: Adiposity and Ild In Human Studiesmentioning

confidence: 99%

Linking Adiposity to Interstitial Lung Disease: The Role of the Dysfunctional Adipocyte and Inflammation

Macklin,

Thompson,

Kawano-Dourado

et al. 2023

Cells

View full text Add to dashboard Cite

show abstract

Anti-Ro-52 antibody is a risk factor for recurrence in interstitial lung disease with positive anti-aminoacyl tRNA synthetase antibody: A single-center, retrospective observational study

Takahashi,

Arita,

Sato

et al. 2024

Preprint

View full text Add to dashboard Cite

Purpose Anti-synthetic syndrome-associated interstitial lung disease (ASS-ILD) recurs in approximately 56% of cases, with recurrence associated with poor long-term prognosis; however, there are few reports on the risk factors for recurrence. While anti-Ro52 antibodies are considered risk factors for rapidly progressing interstitial lung disease in ASS, their role in ASS-ILD recurrence remains unclear. ༷e aimed to evaluate the association between anti-Ro52 antibody and the recurrence of ASS-ILD. Methods This single-center, retrospective cohort study included 97 patients diagnosed with ASS-ILD between January 2010 and August 2023 who underwent induction remission therapy with corticosteroids and immunosuppressive agents (tacrolimus, cyclosporine, and cyclophosphamide). Patients were classified into anti-Ro52 antibody-positive and anti-Ro52 antibody-negative groups. A competing risk analysis was conducted, with the primary endpoint being ASS-ILD recurrence or interstitial pneumonia (IP)-related death and death from other causes as the competing risk. Multivariate analysis identified recurrence factors. Results Forty-four patients were in the anti-Ro52 antibody-positive group and 53 in the anti-Ro52 antibody-negative group. There were no differences between the groups regarding initial and recurrence steroid doses, type of immunosuppressive drugs, and number of discontinued cases. The anti-Ro52 antibody-positive group had a significantly higher rate of recurrent ASS-ILD or ILD-related death in a competing risk analysis (P = 0.011). In multivariate analysis, the anti-Ro52 antibody was identified as an independent risk factor for ASS-ILD recurrence (hazard ratio = 1.84 [1.01–3.36], P = 0.047). Conclusion Anti-Ro52 antibodies are a risk factor for ASS-ILD recurrence.

show abstract

Poor prognostic factors for relapse of interstitial lung disease with anti-aminoacyl-tRNA synthetase antibodies after combination therapy

Matsuda,

Kotani,

et al. 2024

Front. Immunol.

View full text Add to dashboard Cite

IntroductionThis study aimed to identify useful clinical indicators for predicting the relapse of interstitial lung disease (ILD) complicated with anti-aminoacyl-tRNA synthetase (ARS) antibodies (anti-ARS-ILD), being treated with prednisolone and calcineurin inhibitors.MethodsFifty patients with anti-ARS-ILD were enrolled between October 2014 and August 2022. All patients were treated with prednisolone and calcineurin inhibitors as remission induction therapy and followed up for over a year with these combination therapies. We examined patients who experienced ILD relapse after immunosuppressive treatment. We explored the risk factors for predicting ILD relapse in these patients by comparing demographic, clinical, laboratory, and radiological findings and treatments between the relapsed and non-relapsed groups on admission.ResultsOf the 50 patients, 19 (38%) relapsed during a median follow-up of 4.8 years. Univariate and multivariate Cox regression analyses identified the presence of acute/subacute (A/S)-ILD, higher serum aldolase (ALD) and surfactant protein-D (SP-D) levels, and lower %forced vital capacity (FVC) as risk factors for relapse in patients with anti-ARS-ILD. Using the receiver operating curve analysis, ALD ≥6.3 U/L, SP-D ≥207 ng/mL, and %FVC ≤76.8% were determined as the cut-off levels for indicating a poor prognosis. The 5-year relapse rate was significantly higher in patients with A/S-ILD, serum ALD≥6.3 U/L, serum SP-D ≥207 ng/mL, or %FVC of ≤76.8% than in those without these parameters. (P=0.009, 0.0005, 0.0007, 0.0004, respectively) Serum ALD levels were significantly correlated with the disease activity indicators of anti-ARS-ILD.ConclusionThe presence of A/S-ILD, higher serum ALD and SP-D levels, and lower %FVC are useful indicators for predicting anti-ARS-ILD relapse.

show abstract

Influence of obesity in interstitial lung disease associated with anti-aminoacyl-tRNA synthetase antibodies

Cited by 4 publications

References 43 publications

Linking Adiposity to Interstitial Lung Disease: The Role of the Dysfunctional Adipocyte and Inflammation

Linking Adiposity to Interstitial Lung Disease: The Role of the Dysfunctional Adipocyte and Inflammation

Anti-Ro-52 antibody is a risk factor for recurrence in interstitial lung disease with positive anti-aminoacyl tRNA synthetase antibody: A single-center, retrospective observational study

Poor prognostic factors for relapse of interstitial lung disease with anti-aminoacyl-tRNA synthetase antibodies after combination therapy

Contact Info

Product

Resources

About